Interferon-α, -β and -γ induce CXCL11 secretion in human thyrocytes: Modulation by peroxisome proliferator-activated receptor γ agonists

Immunobiology

Volumn 218, Issue 5, 2013, Pages 690-695

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Mancusi, Caterina ^a   Mazzi, Valeria ^a   Pupilli, Cinzia ^b   Centanni, Marco ^c   Ferri, Clodoveo ^d   Ferrannini, Ele ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

CXCL11; Interferon , and ; Rosiglitazone; Thyroid; Thyroiditis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CXCL11 CHEMOKINE; GAMMA INTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOMODULATION; PRIORITY JOURNAL; THYROID FOLLICLE CELL;

CHEMOKINE CXCL11; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERON-GAMMA; PPAR GAMMA; PRIMARY CELL CULTURE; THIAZOLIDINEDIONES; THYROID GLAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875674080     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.08.267     Document Type: Article

References (50)

1. Akeno N., Smith E.P., Stefan M., Huber A.K., Zhang W., Keddache M., Tomer Y. IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J. Immunol. 2011, 186:4693-4706.
2. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Barani L., Ferrannini E., Serio M. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin. Endocrinol. (Oxf) 2006, 64:189-195.
3. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Serio M., Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br. J. Surg. 2006, 93:1226-1231.
4. Antonelli A., Rotondi M., Fallahi P., Grosso M., Boni G., Ferrari S.M., Romagnani P., Serio M., Mariani G., Ferrannini E. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J. Clin. Endocrinol. Metab. 2007, 92:1485-1490.
5. Antonelli A., Ferrari S.M., Frascerra S., Di Domenicantonio A., Nicolini A., Ferrari P., Ferrannini E., Fallahi P. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J. Clin. Endocrinol. Metab. 2011, 96:1859-1863.
6. Antonelli A., Ferrari S.M., Fallahi P., Ghiri E., Crescioli C., Romagnani P., Vitti P., Serio M., Ferrannini E. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine 2010, 50:260-267.
7. Antonelli A., Rotondi M., Ferrari S.M., Fallahi P., Romagnani P., Franceschini S.S., Serio M., Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J. Clin. Endocrinol. Metab. 2006, 91:614-620.
8. Antonelli A., Baj G., Marchetti P., Fallahi P., Surico N., Pupilli C., Malavasi F., Ferrannini E. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 2001, 50:985-991.
9. Antonelli A., Tuomi T., Nannipieri M., Fallahi P., Nesti C., Okamoto H., Groop L., Ferrannini E. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002, 45:1298-1306.
10. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Santini E., Franceschini S.S., Ferrannini E. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J. Clin. Endocrinol. Metab. 2009, 94:1803-1809.
11. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Buonamano A., Ferrannini E., Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J. Clin. Endocrinol. Metab. 2004, 89:5496-5499.
12. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Paolicchi A., Ferrannini E., Serio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur. J. Endocrinol. 2005, 152:171-177.
13. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Romagnani P., Grosso M., Ferrannini E., Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur. J. Endocrinol. 2006, 154:651-658.
14. Antonelli A., Ferri C., Ferrari S.M., Colaci M., Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun. Rev. 2008, 8:18-23.
15. Antonelli A., Ferri C., Galeazzi M., Giannitti C., Manno D., Mieli-Vergani G., Menegatti E., Olivieri I., Puoti M., Palazzi C., Roccatello D., Vergani D., Sarzi-Puttini P., Atzeni F. HCV infection: pathogenesis, clinical manifestations and therapy. Clin. Exp. Rheumatol. 2008, 26:S39-S47.
16. Antonelli A., Ferri C., Ferrari S.M., Colaci M., Sansonno D., Fallahi P. Endocrine manifestations of hepatitis C virus infection. Nat. Clin. Pract. Endocrinol. Metab. 2009, 5:26-34.
17. Antonelli A., Ferrari S.M., Fallahi P., Piaggi S., Paolicchi A., Franceschini S.S., Salvi M., Ferrannini E. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism 2011, 60:277-283.
18. Aubry F., Habasque C., Satie A.P., Jégou B., Samson M. Expression and regulation of the CXC-chemokines, GRO/KC and IP-10/mob-1 in rat seminiferous tubules. Eur. Cytokine Netw. 2000, 11:690-698.
19. Baron S., Tyring S.K., Fleischmann W.R., Coppenhaver D.H., Niesel D.W., Klimpel G.R., Stanton G.J., Hughes T.K. The interferons. Mechanisms of action and clinical applications. JAMA 1991, 266:1375-1383.
20. Caraccio N., Giannini R., Cuccato S., Faviana P., Berti P., Galleri D., Dardano A., Basolo F., Ferrannini E., Monzani F. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J. Clin. Endocrinol. Metab. 2005, 90:1156-1162.
21. Caturegli P., Hejazi M., Suzuki K., Dohan O., Carrasco N., Kohn L.D., Rose N.R. Hypothyroidism in transgenic mice expressing IFN-gamma in the thyroid. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:1719-1724.
22. Chan W.B., Chow C.C., Cockram C.S. Interferon alpha treatment and endocrine disease. J. R. Soc. Med. 2003, 96:481-485.
23. Cole K.E., Strick C.A., Paradis T.J., Ogborne K.T., Loetscher M., Gladue R.P., Lin W., Boyd J.G., Moser B., Wood D.E., Sahagan B.G., Neote K. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 1998, 187:2009-2021.
24. Cox M.A., Jenh C.H., Gonsiorek W., Fine J., Narula S.K., Zavodny P.J., Hipkin R.W. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol. Pharmacol. 2001, 59:707-715.
25. Di Girolamo G., Kauffman M.A., González E., Papouchado M., Ramírez A., Keller G., Carbonetto C., Dabsys S., Vidal A., Sterin-Prync A., Diez R.A. Bioequivalence of two subcutaneous pharmaceutical products of interferon beta la. Arzneimittelforschung 2008, 58:193-198.
26. Fattovich G., Giustina G., Favarato S., Ruol A. A survey of adverse events in 11, 241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol. 1996, 24:38-47.
27. García-López M.A., Sancho D., Sánchez-Madrid F., Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+lymphocytes. J. Clin. Endocrinol. Metab. 2001, 86:5008-5016.
28. Gosset P., Charbonnier A.S., Delerive P., Fontaine J., Staels B., Pestel J., Tonnel A.B., Trottein F. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur. J. Immunol. 2001, 31:2857-2865.
29. Groom J.R., Luster A.D. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 2011, 89:207-215.
30. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
31. Koh L.K., Greenspan F.S., Yeo P.P. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997, 7:891-896.
32. Kung A.W., Jones B.M., Lai C.L. Effects of interferon-gamma therapy on thyroid function, T-lymphocyte subpopulations and induction of autoantibodies. J. Clin. Endocrinol. Metab. 1990, 71:1230-1234.
33. Loetscher P., Pellegrino A., Gong J.H., Mattioli I., Loetscher M., Bardi G., Baggiolini M., Clark-Lewis I. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem. 2001, 276:2986-2991.
34. Lombardi A., Cantini G., Piscitelli E., Gelmini S., Francalanci M., Mello T., Ceni E., Varano G., Forti G., Rotondi M., Galli A., Serio M., Luconi M. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:718-724.
35. Martin A.P., Coronel E.C., Sano G., Chen S.C., Vassileva G., Canasto-Chibuque C., Sedgwick J.D., Frenette P.S., Lipp M., Furtado G.C., Lira S.A. A novel model for lymphocytic infiltration of the thyroid gland generated by transgenic expression of the CC chemokine CCL21. J. Immunol. 2004, 173:4791-4798.
36. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., Libby P., Plutzky J., Luster A.D. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J. Immunol. 2000, 164:6503-6508.
37. Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., Nishioji K., Katagishi T., Nakagawa Y., Tada H., Sawa Y., Mizuno M., Kagawa K., Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 1996, 25:283-291.
38. Proost P., Struyf S., Loos T., Gouwy M., Schutyser E., Conings R., Ronsse I., Parmentier M., Grillet B., Opdenakker G., Balzarini J., Van Damme J. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res. Ther. 2006, 8:R107.
39. Prummel M.F., Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003, 13:547-551.
40. Romagnani P., Rotondi M., Lazzeri E., Lasagni L., Francalanci M., Buonamano A., Milani S., Vitti P., Chiovato L., Tonacchera M., Bellastella A., Serio M. Expression of IP 10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am. J. Pathol. 2002, 161:195-206.
41. Roti E., Minelli R., Giuberti T., Marchelli S., Schianchi C., Gardini E., Salvi M., Fiaccadori F., Ugolotti G., Neri T.M., Braverman L.E. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am. J. Med. 1996, 101:482-487.
42. Rotondi M., Oliviero A., Profice P., Mone C.M., Biondi B., Del Buono A., Mazziotti G., Sinisi A.M., Bellastella A., Carella C. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J. Endocrinol. Invest. 1998, 21:748-752.
43. Rotondi M., Mazziotti G., Biondi B., Manganella G., Del Buono A.D., Montella P., di Cristofaro M., Di Iorio G., Amato G., Carella C. Long-term treatment with interferon-beta therapy for multiple sclerosis and occurrence of Graves' disease. J. Endocrinol. Invest. 2000, 23:321-324.
44. Rotondi M., Stufano F., Lagonigro M.S., La Manna L., Zerbini F., Ghilotti S., Pagliari M.T., Coperchini F., Magri F., Bergamaschi R., Oliviero A., Chiovato L. Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: a clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs. J. Neuroimmunol. 2011, 234:161-164.
45. Schaefer K.L., Denevich S., Ma C., Cooley S.R., Nakajima A., Wada K., Schlezinger J., Sherr D., Saubermann L.J. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm. Bowel Dis. 2005, 11:244-252.
46. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., Flanigan A., Murthy S., Lazar M.A., Wu G.D. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 1999, 104:383-389.
47. Tsubota A., Hirose Y., Izumi N., Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br. J. Clin. Pharmacol. 2003, 55:360-367.
48. Veckman V., Miettinen M., Matikainen S., Lande R., Giacomini E., Coccia E.M., Julkunen I. Lactobacilli and streptococci induce inflammatory chemokine production in human macrophages that stimulates Th1 cell chemotaxis. J. Leukoc. Biol. 2003, 74:395-402.
49. Wills R.J. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet. 1990, 19:390-399.
50. Yamazaki K., Kanaji Y., Shizume K., Yamakawa Y., Demura H., Kanaji Y., Obara T., Sato K. Reversible inhibition by interferons alpha and beta of 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J. Clin. Endocrinol. Metab. 1993, 77:1439-1441.